Initially developed for diabetes, they have produced unprecedented results in weight loss and are hailed by specialists as a potential therapeutic revolution, although concerns remain about their side effects and the risk of taking them outside of medical supervision.

In this context, the introduction of Mounjaro is subject to the same conditions as Wegovy, which has been on the market since October: without reimbursement and subject to very strict prescription requirements.

They can only be prescribed by certain specialists, only to patients with marked obesity, and only when a change in diet alone has not been sufficient for weight loss.